2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Daniel P. Petrylak, MD, discusses enzalutamide plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer.
Daniel P. Petrylak, MD, professor of medicine and urology, coleader, Cancer Signaling Networks, Yale Cancer Center, discusses enzalutamide (Xtandi) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC).
The phase 3 ARCHES trial (NCT02677896) evaluates the safety and efficacy of enzalutamide plus ADT as measured by radiographic progression-free survival (rPFS).
It was found that there was no difference in rPFS and time to first prostate-specific antigen (PSA) relapse in patients with mHSPC, revealing that enzalutamide should be started in all patients regardless of baseline PSA value, Petrylak says. This is important data because it demonstrates that all patients, no matter their PSA, benefited from enzalutamide compared with standard of care ADT alone, Petrylak explains.
This data informs oncologists how to manage their practice and treat patients with mHSPC, Petrylak concludes.